Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV NEPA versus active antiemetic comparators for prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving highly emetogenic chemotherapy
2024-514321-39-00Phase 3Authorised
- Sponsor
- Helsinn
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of fosnetupitant + palonosetron in chemotherapy-induced nausea and vomiting (CINV) (5 arms), sponsored by Helsinn. Planned start May 2025; status: authorised.
02
Drugs
fosnetupitant + palonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2024-514321-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514321-39-00.